Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Shares of Coya Therapeutics, Inc. (NASDAQ:COYA) have been assigned a consensus rating of “Moderate Buy” from the six brokerages that are currently covering the company, MarketBeat reports. One research analyst has rated the stock with a sell rating and five have issued a buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $16.00.

Several brokerages recently commented on COYA. HC Wainwright reiterated a “buy” rating and issued a $18.00 target price on shares of Coya Therapeutics in a report on Monday, February 2nd. BTIG Research raised their price target on Coya Therapeutics from $15.00 to $16.00 and gave the company a “buy” rating in a research report on Thursday, November 13th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Coya Therapeutics in a research note on Wednesday, January 21st. Chardan Capital restated a “buy” rating and set a $14.00 target price on shares of Coya Therapeutics in a research note on Thursday, January 8th. Finally, Lake Street Capital reaffirmed a “buy” rating and issued a $17.00 target price on shares of Coya Therapeutics in a report on Wednesday, November 5th.

Coya Therapeutics Stock Performance

Shares of COYA stock opened at $4.84 on Monday. The stock’s 50 day simple moving average is $5.25 and its 200 day simple moving average is $5.85. Coya Therapeutics has a twelve month low of $3.94 and a twelve month high of $8.29. The company has a market capitalization of $101.25 million, a price-to-earnings ratio of -4.36 and a beta of 0.27.

Coya Therapeutics (NASDAQ:COYA) last announced its quarterly earnings results on Wednesday, November 12th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of $0.02 by ($0.12). Coya Therapeutics had a negative net margin of 462.24% and a negative return on equity of 55.76%. The company had revenue of $3.56 million for the quarter, compared to analyst estimates of $3.70 million. On average, analysts forecast that Coya Therapeutics will post -1.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Coya Therapeutics

Several large investors have recently bought and sold shares of COYA. Citadel Advisors LLC grew its position in Coya Therapeutics by 51.3% in the 3rd quarter. Citadel Advisors LLC now owns 65,240 shares of the company’s stock worth $372,000 after purchasing an additional 22,120 shares during the last quarter. Dauntless Investment Group LLC raised its position in shares of Coya Therapeutics by 199.5% during the third quarter. Dauntless Investment Group LLC now owns 153,021 shares of the company’s stock valued at $872,000 after buying an additional 101,932 shares during the last quarter. CM Management LLC lifted its stake in shares of Coya Therapeutics by 16.7% in the fourth quarter. CM Management LLC now owns 350,000 shares of the company’s stock valued at $2,030,000 after buying an additional 50,000 shares during the period. Oppenheimer & Co. Inc. bought a new stake in shares of Coya Therapeutics in the fourth quarter valued at about $81,000. Finally, Prosperity Wealth Management Inc. grew its position in Coya Therapeutics by 16.4% during the third quarter. Prosperity Wealth Management Inc. now owns 23,800 shares of the company’s stock worth $136,000 after buying an additional 3,350 shares in the last quarter. 39.75% of the stock is currently owned by institutional investors and hedge funds.

Coya Therapeutics Company Profile

Coya Therapeutics, Inc (NASDAQ: COYA) is a clinical‐stage biotechnology company focused on the discovery and development of first‐in‐class therapeutics for fibrotic diseases and cancer. The company’s scientific approach centers on targeting UNC-45A, a molecular chaperone implicated in the regulation of cell motility, proliferation and extracellular matrix deposition. By modulating the activity of UNC-45A, Coya aims to address underlying mechanisms of tissue fibrosis and tumor progression that currently lack effective treatments.

Coya’s pipeline is anchored by two lead programs: COY-001, a small‐molecule inhibitor in preclinical development for fibrotic disorders such as idiopathic pulmonary fibrosis and systemic sclerosis, and COY-002, which is being advanced toward the clinic for certain solid tumors.